
## Giovanni Corso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6830675/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23.	7.1	540
2	Germline CDH1 deletions in hereditary diffuse gastric cancer families. Human Molecular Genetics, 2009, 18, 1545-1555.	2.9	185
3	Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications. Breast, 2017, 34, S82-S84.	2.2	181
4	Number of lymph node metastases and its prognostic significance in early gastric cancer: A multicenter italian study. Journal of Surgical Oncology, 2006, 94, 275-280.	1.7	149
5	Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer. Journal of Clinical Oncology, 2013, 31, 868-875.	1.6	145
6	CDH1 germline mutations and hereditary lobular breast cancer. Familial Cancer, 2016, 15, 215-219.	1.9	99
7	Oncogenic mutations in gastric cancer with microsatellite instability. European Journal of Cancer, 2011, 47, 443-451.	2.8	92
8	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. European Journal of Surgical Oncology, 2021, 47, 804-812.	1.0	91
9	Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer, 2012, 12, 8.	2.6	85
10	E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. European Journal of Cancer, 2011, 47, 631-639.	2.8	69
11	Oncological Outcomes of Nipple-Sparing Mastectomy: A Single-Center Experience of 1989 Patients. Annals of Surgical Oncology, 2018, 25, 3849-3857.	1.5	68
12	Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. Journal of Medical Genetics, 2018, 55, 431-441.	3.2	68
13	Update on the Feasibility and Progress on Robotic Breast Surgery. Annals of Surgical Oncology, 2019, 26, 3046-3051.	1.5	63
14	Axillary surgery in breast cancer: An updated historical perspective. Seminars in Oncology, 2020, 47, 341-352.	2.2	63
15	Eâ€cadherin deregulation in breast cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 5930-5936.	3.6	59
16	E-cadherin germline mutation carriers: clinical management and genetic implications. Cancer and Metastasis Reviews, 2014, 33, 1081-1094.	5.9	48
17	Hereditary diffuse gastric cancer and E-cadherin: Description of the first germline mutation in an Italian family. European Journal of Surgical Oncology, 2007, 33, 448-451.	1.0	41
18	Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. European Journal of Surgical Oncology, 2014, 40, 1203-1208.	1.0	41

#	Article	IF	CITATIONS
19	Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. European Journal of Surgical Oncology, 2007, 33, 1061-1067.	1.0	40
20	Metaplastic breast cancer: Prognostic and therapeutic considerations. Journal of Surgical Oncology, 2021, 123, 61-70.	1.7	40
21	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers, 2020, 12, 1598.	3.7	37
22	History, Pathogenesis, and Management of Familial Gastric Cancer: Original Study of John XXIII's Family. BioMed Research International, 2013, 2013, 1-8.	1.9	36
23	A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BrCA Mutation. Annals of Surgery, 2022, 276, 11-19.	4.2	36
24	Contralateral Axillary Lymph Node Metastases from Breast Carcinoma: Is it Time to Review TNM Cancer Staging?. Annals of Surgical Oncology, 2020, 27, 4488-4499.	1.5	31
25	Different Pathological Features and Prognosis in Gastric Cancer Patients Coming From High-Risk and Low-Risk Areas of Italy. Annals of Surgery, 2009, 250, 43-50.	4.2	30
26	Multiple primary non-breast tumors in breast cancer survivors. Journal of Cancer Research and Clinical Oncology, 2018, 144, 979-986.	2.5	29
27	Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. European Journal of Human Genetics, 2013, 21, 1383-1388.	2.8	26
28	Standard and controversies in sentinel node in breast cancer patients. Breast, 2019, 48, S53-S56.	2.2	26
29	High Incidence of Familial Gastric Cancer in Tuscany, a Region in Italy. Oncology, 2007, 72, 243-247.	1.9	25
30	Nipple-sparing mastectomy with different approaches: surgical incisions, complications, and cosmetic results. Preliminary results of 100 consecutive patients at a single center. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2018, 71, 1751-1760.	1.0	22
31	Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis. Annals of Surgical Oncology, 2022, 29, 6646-6657.	1.5	22
32	Prognosis and outcome in CDH1-mutant lobular breast cancer. European Journal of Cancer Prevention, 2018, 27, 237-238.	1.3	21
33	Geographical Distribution of E-cadherin Germline Mutations in the Context of Diffuse Gastric Cancer: A Systematic Review. Cancers, 2021, 13, 1269.	3.7	21
34	Validation of a Novel Nomogram for Prediction of Local Relapse after Surgery for Invasive Breast Carcinoma. Annals of Surgical Oncology, 2020, 27, 1864-1874.	1.5	20
35	Redefinition of familial intestinal gastric cancer: clinical and genetic perspectives. Journal of Medical Genetics, 2021, 58, 1-11.	3.2	20
36	Gastric Cardia Carcinoma is Associated with the Promoter -77T>C Gene Polymorphism of X-Ray Cross-Complementing Group 1 (XRCC1). Journal of Gastrointestinal Surgery, 2009, 13, 2233-2238.	1.7	18

#	Article	IF	CITATIONS
37	CDH1 C-160A promoter polymorphism and gastric cancer risk. European Journal of Cancer Prevention, 2009, 18, 46-49.	1.3	18
38	Familial gastric cancer and Li-Fraumeni syndrome. European Journal of Cancer Care, 2010, 19, 377-381.	1.5	18
39	Oncoplastic Breast-Conserving Surgery for Synchronous Multicentric and Multifocal Tumors: Is It Oncologically Safe? A Retrospective Matched-Cohort Analysis. Annals of Surgical Oncology, 2022, 29, 427-436.	1.5	18
40	Familial gastric cancer: update for practice management. Familial Cancer, 2011, 10, 391-396.	1.9	17
41	Granular cell tumor of the breast: Molecular pathology and clinical management. Breast Journal, 2018, 24, 778-782.	1.0	16
42	HPV infection and breast cancer. Results of a microarray approach. Breast, 2018, 40, 165-169.	2.2	15
43	Surgical Resection Margins after Breast-Conserving Surgery: Senonetwork Recommendations. Tumori, 2016, 102, 284-289.	1.1	14
44	Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. European Journal of Surgical Oncology, 2018, 44, 957-962.	1.0	14
45	lpsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients. Oncology, 2018, 95, 147-155.	1.9	14
46	CDH1 germline mutations in families with hereditary lobular breast cancer. European Journal of Cancer Prevention, 2022, 31, 274-278.	1.3	14
47	Hereditary breast cancer. European Journal of Cancer Prevention, 2020, Publish Ahead of Print, 311-314.	1.3	14
48	Breast Cancer Surgery: New Issues. Current Oncology, 2021, 28, 4053-4066.	2.2	12
49	Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review. Future Oncology, 2020, 16, 395-412.	2.4	11
50	Frequency of CDH1 Germline Mutations in Non-Gastric Cancers. Cancers, 2021, 13, 2321.	3.7	11
51	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast, 2021, 59, 94-101.	2.2	11
52	ls Circulating D-Dimer Level a Better Prognostic Indicator than Cea in Resectable Colorectal Cancer? Our Experience on 199 Cases. International Journal of Biological Markers, 2010, 25, 171-176.	1.8	10
53	Overexploring and overtreating the axilla. Breast, 2017, 31, 290-294.	2.2	9
54	Familial gastric cancer and germline mutations of E-cadherin. Annali Italiani Di Chirurgia, 2012, 83, 177-82.	0.1	9

#	Article	IF	CITATIONS
55	Effect of low density lipoprotein fatty acid composition on copper-induced peroxidation: 1H-nuclear magnetic resonance analysis. Clinica Chimica Acta, 1997, 258, 193-200.	1.1	8
56	Clinical implication of E-cadherin deficiency in lobular breast cancer. Breast Cancer Research and Treatment, 2019, 173, 751-752.	2.5	8
57	<i>CDH1</i> germline mutations in healthy individuals from families with the hereditary diffuse gastric cancer syndrome. Journal of Medical Genetics, 2022, 59, 313-317.	3.2	8
58	Sentinel lymph node biopsy management after neoadjuvant treatment for breast cancer care. Future Oncology, 2018, 14, 1423-1426.	2.4	7
59	Impact of COVID-19 pandemic on clinical and surgical breast cancer management. EClinicalMedicine, 2020, 26, 100523.	7.1	7
60	Immediate breast reconstruction with latissimus dorsi flap for patients with local recurrence of breast cancer. European Journal of Surgical Oncology, 2020, 46, 1013-1020.	1.0	7
61	How Useful Are Tumor Markers in Detecting Metastases with FDG-PET/CT during Breast Cancer Surveillance?. Oncology, 2020, 98, 714-718.	1.9	5
62	Implementation of the BRESO Theoretical and practical knowledge curriculum for European Breast Surgeons: The time has come. European Journal of Surgical Oncology, 2020, 46, 715-716.	1.0	5
63	Tenâ€year outcome results of cT4 breast cancer after neoadjuvant treatment. Journal of Surgical Oncology, 2021, 124, 1242-1250.	1.7	5
64	Pleiotropic cancer manifestations of germline <i>CDH1</i> mutations: Risks and management. Journal of Surgical Oncology, 2022, , .	1.7	5
65	Progress in prostate cancer prevention. European Journal of Cancer Prevention, 2022, 31, 554-557.	1.3	5
66	The Veronesi quadrantectomy: an historical overview. Ecancermedicalscience, 2017, 11, 743.	1.1	4
67	ASO Author Reflections: Clinical Implication of Nomograms in the Breast Oncology Field. Annals of Surgical Oncology, 2020, 27, 1875-1876.	1.5	4
68	Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated. Breast Cancer Research and Treatment, 2021, 188, 511-524.	2.5	4
69	Long-term outcome and axillary recurrence in elderly women (≥70 years) with breast cancer: 10-years follow-up from a matched cohort study. European Journal of Surgical Oncology, 2021, 47, 1593-1600.	1.0	4
70	Anatomy is not enough: the crucial role of biology and genetics in AJCC eighth edition of the TNM classification for breast cancer. Annals of Translational Medicine, 2019, 7, S34-S34.	1.7	4
71	Does failed mapping predict sentinel lymph node metastasis in cNO breast cancer?. Future Oncology, 2022, 18, 193-204.	2.4	4
72	Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy. Annali Italiani Di Chirurgia, 2017, 88, 201-205.	0.1	4

#	Article	IF	CITATIONS
73	A propensity score–matched analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy in breast cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1085-1093.	2.5	4
74	Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations. Seminars in Oncology, 2022, , .	2.2	4
75	Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers. Annals of Surgical Oncology, 2022, 29, 5821-5825.	1.5	4
76	Mutual exclusion of CDH1 and BRCA germline mutations in the pathway of hereditary breast cancer. Archives of Gynecology and Obstetrics, 2018, 297, 1067-1068.	1.7	3
77	Clinical criteria revision for hereditary lobular breast cancer associated with E-cadherin germline mutations. Personalized Medicine, 2018, 15, 153-155.	1.5	3
78	Could radiotherapy play a major role in misidentification of sentinel lymph node in breast cancer recurrence?. Radiotherapy and Oncology, 2019, 131, 237-238.	0.6	3
79	Letter Regarding: Is Prophylactic Total Gastrectomy Always Indicated in CDH1 Germline Mutant Carriers?. Journal of Surgical Research, 2020, 255, 647-648.	1.6	3
80	Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology. European Journal of Surgical Oncology, 2021, 47, 2499-2505.	1.0	3
81	Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery. Cancers, 2022, 14, 3245.	3.7	3
82	A Rare Case of Primary Small Bowel Adenocarcinoma with Intussusception. Tumori, 2010, 96, 355-357.	1.1	2
83	Ultraviolet radiation resistance-associated polyadenine deletions in human gastric cancer. Human Pathology, 2012, 43, 961-962.	2.0	2
84	Breast cancer with rare metastatic manifestation. Future Oncology, 2019, 15, 2437-2440.	2.4	2
85	E-cadherin germline mutations in MÄori population. Future Oncology, 2019, 15, 1291-1294.	2.4	2
86	De-escalation treatment of axilla in breast cancer. Clinical and Translational Oncology, 2020, 22, 445-446.	2.4	2
87	E-Cadherin (CDH1 Gene) Germline Mutations in Gastric Cancer: Evolutions and Innovations. Cancers, 2020, 12, 2920.	3.7	2
88	Is Nipple-Sparing Mastectomy Indicated after Previous Breast Surgery? A Series of 387 Institutional Cases. Plastic and Reconstructive Surgery, 2021, 148, 21-30.	1.4	2
89	CDH1 structural alterations as novel prognostic biomarker in gastric cancer patients Journal of Clinical Oncology, 2011, 29, 42-42.	1.6	2
90	Hereditary Gastric Cancer: A New Syndrome. Updates in Surgery Series, 2021, , 37-50.	0.1	2

#	Article	IF	CITATIONS
91	ASO Visual Abstract: Oncoplastic Breast-Conserving Surgery forÂSynchronousÂMulticentric and Multifocal Tumors: is it Oncologically Safe? A Retrospective Matched-Cohort Analysis. Annals of Surgical Oncology, 2021, 28, 764-765.	1.5	2
92	Assessment of a tumor bank: a thirty years experience of the University of Siena (Italy). Cell and Tissue Banking, 2015, 16, 283-286.	1.1	1
93	Prognostic impact of germline mutations in inherited cancer syndromes. Future Oncology, 2017, 13, 2125-2127.	2.4	1
94	Supernumerary Axillary Breast Cancer. Breast Journal, 2017, 23, 246-248.	1.0	1
95	Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED). Breast Cancer Research and Treatment, 2018, 171, 693-699.	2.5	1
96	Familial lobular breast cancer: Is testing for germline CDH1 mutations necessary?. European Journal of Surgical Oncology, 2019, 45, 1760-1761.	1.0	1
97	Metaplastic Breast Carcinoma and Other Triple-Negative Subtype Breast Cancers: Which Is Worst?. Annals of Surgical Oncology, 2021, 28, 5438-5439.	1.5	1
98	Impact of radiation and hormonal therapy on the locoregional recurrence of elderly breast cancer: Are these necessary after breastâ€conserving surgery?. Cancer, 2021, 127, 2807-2808.	4.1	1
99	Germline mutations of the E-cadherin gene (CDH1) in early onset gastric cancer. Seminars in Oncology, 2020, 47, 125-126.	2.2	1
100	Validation of a panel of risk factors for predicting breast cancer reappearance Journal of Clinical Oncology, 2019, 37, e12004-e12004.	1.6	1
101	Microsatellite instability in gastrointestinal cancers. European Journal of Human Genetics, 2022, 30, 996-997.	2.8	1
102	<i>PIK3CA</i> oncogenic mutations in neoadjuvant treatments for breast cancer. Biomarkers in Medicine, 2017, 11, 519-521.	1.4	0
103	Axillary blue sentinel lymph node: an unusual tattoo?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1940-1941.	6.4	0
104	Intra-operative radiotherapy management for breast cancer treatment in patients with pseudoxanthoma elasticum: A case report. Breast Journal, 2018, 24, 385-387.	1.0	0
105	Second Reply to: "Metaplastic Breast Carcinoma and Other Triple-Negative Subtype Breast Cancers: Which is the Worst?― Annals of Surgical Oncology, 2021, 28, 811-812.	1.5	0
106	Oncogenic mutations in MAPK cascade as novel molecular biomarkers for treatment of gastric cancer patients with EGFR inhibitors Journal of Clinical Oncology, 2011, 29, 39-39.	1.6	0
107	Oncogenic mutations in colorectal cancer, indications for anatomical sites, and targeted intervention Journal of Clinical Oncology, 2013, 31, e22037-e22037.	1.6	0